Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: an Open-label, Phase 1, Dose-escalation, First-in-human Study By admin / 02/20/2018
Long-term follow-up of the PI3K delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. By admin / 06/03/2016
Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily Pi3k Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. By admin / 06/02/2015
TGR-1202, a Novel Once Daily Pi3K Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. By admin / 12/09/2014
Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. By admin / 06/13/2014
Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. By admin / 05/30/2014
